Arbutus Biopharma | Investor Presentation Deck | 28 slides — playbook

Arbutus Biopharma | Investor Presentation Deck | 28 slides

Arbutus Biopharma · 2023-08

arc beats above · slides in the middle · loops below · scroll → 2 LOOPS

Deck intelligence map

3

coverage by narrative range · generated from this deck JSON

Narrative range 11 total

Metadata

Components

Metrics

Tools

Frameworks

Beats

Loops

Problem (Identify pain) 1 slides 100% 1/1 slides 100% 1/1 slides · 7 hits

— 0/1 slides

— 0/1 slides

100% 1/1 slides 100% 1/1 slides · 2 hits 100% 1/1 slides Agitate (Make it worse) 2 slides 100% 2/2 slides 100% 2/2 slides · 11 hits

— 0/2 slides

— 0/2 slides

100% 2/2 slides 100% 2/2 slides · 3 hits 100% 2/2 slides Solution (Provide relief) 8 slides 100% 8/8 slides 100% 8/8 slides · 36 hits

— 0/8 slides

12.5% 1/8 slides

— 0/8 slides

100% 8/8 slides 100% 8/8 slides

Slide inventory

28

every slide · same image gating as the playbook

01

front_matter

Open slide detail

02

other

Open slide detail

03

present_solution

Open slide detail

04

The slide uses a structured grid layout to present key value drivers.summarize

Open slide detail

05

The slide uses a Gantt-style visualization to show drug development stages.plan_implementation

Open slide detail

06

The slide uses a four-column layout to structure the disease overview.establish_context

Open slide detail

07

Uses a geographic map and a nested circle diagram to illustrate the treatment gap.frame_problem

Open slide detailBeat · Problem (Identify pain)Loop · Cost Of Inaction

08

The slide uses a process-oriented flow diagram to explain the mechanism of action for a combination therapy.present_solution

Open slide detailBeat · Agitate (Make it worse)Loop · Cost Of Inaction

09

The slide highlights the mechanism of action targeting multiple HBV transcripts.present_solution

Open slide detailBeat · Solution (Provide relief)Loop · Jobs To Be Done

10

The slide outlines study design for Part 1, 2, and 3 of a clinical trial for chronic hepatitis B (cHBV).analyze_data

Open slide detailBeat · Solution (Provide relief)Loop · Jobs To Be Done

11

Data presented at Global Hepatitis Summit 2023. Includes specific cohort N values and standard error (SE) in parentheses.analyze_data

Open slide detailBeat · Solution (Provide relief)Loop · Jobs To Be Done

12

The slide displays six longitudinal line charts representing different patient cohorts, with specific callouts for clinical outcomes.show_traction

Open slide detailBeat · Solution (Provide relief)Loop · Jobs To Be Done

13

Clinical trial data showing individual patient responses over time.show_traction

Open slide detailBeat · Solution (Provide relief)Loop · Jobs To Be Done

14

Data presented at EASL 2022. Shows correlation between T-cell activation and HBsAg reduction.show_traction

Open slide detailBeat · Solution (Provide relief)Loop · Jobs To Be Done

15

The slide uses a bulleted list to present key safety outcomes, including lack of serious adverse events and specific laboratory findings.summarize

Open slide detailBeat · Solution (Provide relief)Loop · Jobs To Be Done

16

summarize

Open slide detailBeat · Solution (Provide relief)Loop · Jobs To Be Done

17

The slide outlines a clinical trial timeline and key efficacy metrics for a chronic hepatitis B (cHBV) treatment.plan_implementation

Open slide detail

18

The slide outlines two parallel study arms with randomization at week 24.plan_implementation

Open slide detail

19

The slide details a specific licensing deal, including financial terms and partner background.other

Open slide detail

20

The slide uses a three-column layout to highlight key value propositions.present_solution

Open slide detail

21

Includes a line chart for efficacy over time and two bar charts for pharmacokinetic concentrations in plasma vs liver.show_traction

Open slide detail

22

Includes IC50 value and IFN-y fold increase data.present_solution

Open slide detail

23

The slide uses a three-column layout to explain the scientific basis and product profile.present_solution

Open slide detail

24

establish_context

Open slide detail

25

Includes a schematic of the SARS-CoV-2 genome and protein structure, alongside specific drug development strategies.present_solution

Open slide detail

26

The slide uses a three-pillar framework to summarize the drug's value proposition.present_solution

Open slide detail

27

Includes financial metrics (cash balance, runway, burn) as context for the milestones.plan_implementation

Open slide detail

28

state_next_steps

Open slide detail